Tiagabine (TGB) and vigabatrin (VGB) are two novel anticonvulsant compounds reported to exert their pharmacological effects via an action on the y-aminobutyric acid (GABA) system. We have investigated the effects of acute exposure of these drugs on the uptake of GABA into rat cortical astrocytes in primary culture. Astrocytes were prepared from the cerebral cortices of one-day-old rat pups by a mechanical dissociation technique and were assayed for GABA uptake activity after 21 days in culture. Tiagabine (100-300 nM) and VGB (100~~) reduced GABA uptake when compared to control at four hours post-exposure. GABA uptake was also reduced following eight and 24 hour exposures to 20011~ TGB. A combination of TGB (20011~) and VGB (100~~) treatments reduced GABA uptake when compared to both control and VGB treated cultures. These results support the efficacy of TGB as a GABA uptake inhibitor and suggest that VGB may also exert an effect by this mechanism.
INTRODUCTION
Epilepsy is one of the most common neurological disorders affecting an estimated 50 million people world-wide'. The majority of the epileptic population can be adequately controlled with existing antiepileptic drugs (AEDs), although 20% of patients remain resistant to currently available treatment*.
Recent additions to the clinician's armamentarium have, however, improved the pharmacological treatment of epilepsy, particularly in terms of side-effect profiles3.
Two such novel compounds are vigabatrin (VGB) and tiagabine (TGB). Both drugs have been reported to exert their anticonvulsant actions via specific effects on the y-aminobutyric acid (GABA) system, VGB by an irreversible inhibition of the enzyme GABA-transaminase (GABA-T) and TGB by blockade of neuronal and glial GABA uptake4*'.
While experimental evidence supports a single mechanism of action for TGB6, a variety of reports would suggest otherwise for VGB. The diverse range of experimental anticonvulsant profiles exhibited by a variety of neuroactive compounds, all of which are proposed to act as inhibitors of brain GABA-T', might suggest the contribution of secondary mechanisms of action. Similarly, Bemasconi and colleagues' demonstrated that the anticonvulsant effects of VGB in animal seizure models are not related to the time of maximal GABA-T inhibition.
Perhaps the most pertinent observation, however, is one of rebound seizures immediately upon clinical withdrawal of the drug'. Such an effect would be inconsistent with a compound which irreversibly inhibits an enzyme in the brain. As a result of these experimental and clinical observations with VGB, we have investigated its action on GABA uptake into rat cortical astrocytes in primary culture and compared these effects to those obtained with TGB.
MATERIALS
One-day-old rat pups were obtained from a breeding colony of Sprague Dawley rats housed at the Joint Animal Facility, University of Glasgow. Dulbecco's modified Eagle medium (DMEM), house serum (HS), L-glutamine, penicillin and streptomycin were all obtained from Gibco BRL (Paisley, U.K.). All other chemicals (reagent grade) were obtained from the Sigma Chemical Company (Poole, U.K.). Radiolabelled GABA (y-['4C(U)]-aminobutyric acid) was obtained from NEN Research Products (Stevenage, U.K.). VGB (D,L-4-aminohex-5-enoic acid) and TGB ((R-)-(-)-l-[4,4-Bis(3-methyl-2-thienyl)-3-butenyll-3-piperidine-carboxylic acid, hydrochloride) were obtained from Marion Merrell Dow (Winnersh, U.K.) and Novo Nordisk A/S (Bagsvaerd, Denmark), respectively.
METHODS

Primary culture of cerebral cortical astrocytes
This method was devised from modifications of the methods of Larsson and co-workers" and Bender and Hertz"'. The cerebral cortices of one-day-old rat pups were removed under aseptic conditions and cleared of attached olfactory bulbs, basal ganglia, hippocampal formations and meningeal membranes. The dissected neopallia were then cut into small cubes (0.5 mm') by two passes (at 90') in a McIlwain tissue chopper (Mickle Laboratory Engineering Company Ltd, Gomshall, U.K.). The chopped tissue was transferred to a sterile glass filter (80 pm nylon mesh; Lockertex Ltd., Warrington, U.K.) and the filtrate collected in a sterile beaker. The chopped material was washed through the filter with culture medium (DMEM supplemented with 20% (v/v) HS, 2.5 mM L-glutamine, 100 I.U./ml penicillin, and 100 pg/rnl streptomycin) to give a final volume of 3 ml/brain. The filtrate was then passed through a sterile needle (BD Microlance 21G 0.8 X 40) three times. The volume of the resulting suspension was adjusted with culture medium to allow a 3 ml aliquot per culture dish in a ratio of 1 brain to 3 dishes. A 3 ml volume of the final cell suspension was plated onto 60 X 15 mm Falcon Primaria culture dishes (A + J Beveridge, Edinburgh, U.K.). The cultures were maintained at 37°C in an environment of 95% sir/5% CO2 with a humidity of 290%. The culture medium (3 ml) was replaced every 3-4 days throughout. The HS concentration was reduced to 10% at the first medium change with a final reduction to 5% at the second change. After 14 days in culture the medium was supplemented with 0.25 mM 3'5'-dibutyryl cyclic adenosine monophosphate (CAMP) to induce cell differentiation. Penicillin and streptomycin were omitted from the medium at this stage following reports that penicillin may interfere with GABAergic function'*. The cultures were employed for the study of GABA uptake seven days after supplementation with CAMP.
[14C]-GABA uptake into cultured astrocytes This method was devised from modifications of the methods of Larsson and co-workers" and Yu and colleagues'3. A standard balanced salt solution (BSS) was used throughout the investigations of [14C]-GABA uptake. Its composition was as follows: 136 mM NaCl, 5 mM KCI, 0.8 mu MgS04, 2.6 mM NaHC03, 0.4 mM KH2P04, 0.34 mM Na2HP04, 1.3 mM CaCl,, 5.6 mM D-glucose and 15 mM HEPES. The solution was adjusted to pH 7.4 with 1 M NaOH and stored, at 4"C, for up to one week. BSS was warmed to 37°C prior to use. Cultures for investigation were removed from the incubator and the existing medium aspirated. Cultures were washed twice (2 X 2 ml) with BSS before being returned to the incubator in a further volume of BSS (3 ml) for an equilibration period of 20minutes. The prewashed cultures were then removed from the incubator and the existing BSS aspirated. This solution was replaced by BSS (2 ml) containing the drug concentrations appropriate to the individual experiment. Control plates received BSS alone. All culture plates were returned to the incubator for a further incubation period (l-24 hours). After the incubation period, a further 1 ml of BSS (with appropriate control/drug treatment) containing 150 PM [14C]-GABA (specific activity = 1 mCi/mmol) was added to each plate. Incubation (37°C) was allowed to continue for five minutes before the cultures were washed with five volumes (2 ml) of BSS. Cells were removed from the plates by scraping in 1 M NaOH (1 ml). Aliquots were taken for protein determination by the BIORAD method and liquid scintillation counting in 6 ml of Picofluor 40 scintillation fluid (Canberra Packard, Pangboume, U.K.). A Canberra Packard 2OOOCA TRI-CARB liquid scintillation counter (Pangboume, U.K.) was employed to analyse GABA uptake in individual cultures in comparison to the dpm of standard solutions containing known amounts of radioligand. Results were quantified by the relation of GABA uptake to the protein concentration and expressed as pmol/minute/mg protein in individual cultures.
Determination of protein concentration
Protein concentrations were determined by the, sensitive BIORAD method which relies on the colour change of a dye (Coomassie Brilliant Blue G-250). Standards were prepared over the range 5-20 pg/ml bovine serum albumin and samples of unknown protein concentration were also diluted into this range. BIORAD dye reagent was diluted 1:l with water and added to standards and samples alike. Tubes were mixed and incubated at room temperature for 5 minutes and then read at 595 nm in a spectrophotometer (MR5000, Dynatech Ltd., Guernsey). Results were corrected for dilution and expressed in mg/ml.
EXPERIMENTAL PROTOCOL
The following studies were designed to investigate the dose-and time-dependent effects of both TGB and VGB on GABA uptake into primary cultures of rat cortical astrocytes. Individual studies employed control (untreated) groups and between 12 and 20 plates per group. In the combination experiment (Study no. 5), results were compared by two sample r-test. 231 
RESULTS
Study 1
TGB (100-300 IUII) significantly reduced GABA uptake into primary cultures of rat cortical astrocytes following a four hour exposure (Fig. 1) . All other doses of TGB were without effect.
Study 2
VGB (100 and 250 PM) significantly reduced GABA uptake into primary cultures of rat cortical astrocytes following a four hour exposure (Fig. 2) . All other doses of VGB were without effect.
Study 3
TGB (200 nM) significantly reduced GABA uptake into primary cultures of rat cortical astrocytes at 4, 8 and 24 hours post-exposure (Fig. 3) . TGB was without effect at all other time points investigated.
Study 4 VGB (100~~)
was without effect on GABA uptake into primary cultures of rat cortical astrocytes at all of the time points investigated (Fig. 4) .
Study 5 TGB (200n~), VGB (100~~) and combination treatments all significantly reduced GABA into primary cultures of rat cortical astrocytes when compared to control (Fig. 5) .
DISCUSSION
The aims of these studies were to investigate the effects of TGB and VGB, alone and in combination, on the uptake of [14C]-GABA into rat cortical astrocytes in primary culture.
These drugs have previously been proposed to exert their pharmacological actions via single and specific effects on the GABAergic system4*5.
TGB belongs to a new class of AEDs, derived from nipecotic acid and believed to exert their anticonvulsant action by blockade of GABA uptake into neurones and glial cell@. Recent evidence has suggested that GABA uptake is mediated by four distinct transporter proteinsI and that TGB is predominantly active at the transporter termed 'GAT-1' and weakly active at 'GAT-3'.
TGB is effective against audiogenic seizures in DBA/2 mice5, the motor manifestations of amygdaloid kindled seizurer? and the tonic and clonic components of pentylenetetrazol-induced seizures in both rats and mice5. It has also been proposed to have efficacy against tonic seizures induced by maximal electroshocki6. TGB is currently undergoing phase III clinical trial for the treatment of epilepsy and initial reports suggest that the drug is active against both partial and secondary generalized seizures3.
In these studies, TGB reduced GABA uptake into rat cortical astrocytes in a dose-specific manner. Its concentration-effect profile appeared to be U-shaped, however, making determination of an IC50 impossible. A similar dose-related pattern has been reported with TGB in whole animal seizure models5. The reason for this phenomenon remains unknown, and although higher drug doses are possibly cytotoxic, no parallel reduction in the protein content of cultures was observed in the above studies. Another surprising observation from these studies was the latency to onset of TGB action on GABA uptake, with the drug only being active after at least four hours exposure. This would not appear to concur with the rapid onset of TGB action in whole animal seizure models following parenteral administration5.
One might speculate that direct application of TGB to the cell surface should result in immediate effect. Further studies employing a wider range of time intervals from 0 to 4 hours are required in an attempt to clarify this apparent discrepancy. Vigabatrin was the first drug to enter regular clinical use, having been designed specifically for the treatment of epilepsy". It has been proposed to exert its anticonvulsant effects by an irreversible inhibition of GABA-p, the enzyme responsible for the metabolic degradation of the inhibitory neurotransmitter GABA. Vigabatrin has demonstrated efficacy against a range of experimental seizures including those induced by picrotoxin' and amygdaloid kindling"
and is also effective in genetic models of reflex epilepsy".
At concentrations of 100 and 250~~, VGB significantly blocked astrocytic. GABA uptake. These concentrations are close to that reported as the IC50 for inhibition of GABA-T in the same cell type". This previously unreported mechanism of VGB action might help to explain the diverse range of experimental anticonvulsant profiles exhibited by a variety of GABA-T inhibitors'.
It may also underlie the lack of relationship between the time of maximal GABA-T inhibition and the anticonvulsant effects of VGB in animal seizure models' and the observation of rebound seizures immediately upon clinical withdrawal of the drug'.
If one considers the structural similarity between VGB and GABA, it is possible to speculate that the blockade of GABA uptake afforded by VGB may be the result of a simple competitive reaction between the two molecules at one or more of the four reported GABA uptake carriers .
I4 Although previous studies have suggested that VGB is not a substrate for the 'GABA transporter'21, the drug is believed to enter cells via some high affinity uptake system".
With recent evidence proposing the existence of multiple GABA uptake carriers14, it is possible that VGB has a specific action at one or more of these newly discovered targets. The GABA uptake carrier 'GAT-3' might represent the most likely site of VGB action in this respect. p-alanine, a specific substrate of GABA-T22, has been shown to selectively block GABA transport via the 'GAT3' carrier. It is possible that structural similarities facilitate the binding of GABA, @alanine and VGB at the active sites of both GABA-T and the 'GAT-3' transporter.
In cultures exposed to a combination of both TGB and VGB, the inhibition of GABA uptake was greater than that observed when either drug was administered alone. This effect did, however, appear to be i&a-additive and would thus suggest a similar site of action for both drugs. If TGB and VGB were to act at independent uptake sites one would expect to observe a total inhibition of GABA uptake equal to the sum of inhibitions observed with both drugs alone. This evidence might support a contributory role for VGB on the TGB-mediated blockade of GABA uptake at the 'GAT-3' transporter.
In conclusion, these results suggest that both TGB and VGB block GABA uptake into primary cultures of rat cortical astrocytes. Further studies to determine the basis of the U-shaped dose-response to TGB and its lack of effect prior to four hours are required. In terms of VGB, a more detailed evaluation of this novel mechanism is planned. Further investigations of its dose-and time-dependency and cell specificity, together with evaluation of the relationship between this and the intracellular effects of VGB are clearly required. Characterization of the GABA uptake blockade observed with VGB may help to determine its relative importance as an additional mechanism of anticonvulsant action.
